19. Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the ageing brain: A review and practical application. Aging Health. 2008; 4: 311–320.
20. Ramos H, Moreno L, Pérez-Tur J, et al. CRIDECO Anticholinergic Load Scale: An Updated Anticholinergic Burden Scale. Comparison with the ACB Scale in Spanish Individuals with Subjective Memory Complaints. J Pers Med. 2022 Feb 3; 12(2): 207.
21. Ganz ML, Liu J, Zou KH, Bhagnani T, Luo X. Real-world characteristics of elderly patients with overactive bladder in the United States. Curr Med Res Opin. 2016; 32(12): 1997–2005.
22. Gutiérrez-Valencia M, Aldaz Herce P, Lacalle-Fabo E, et al. Prevalence of polypharmacy and associated factors in older adults in Spain: Data from the National Health Survey 2017. Med Clin (Barc). 2019; 153(4): 141–150.
23. Hanlon P, Quinn TJ, Gallacher KI, et al. Assessing Risks of Polypharmacy Involving Medications With Anticholinergic Properties. Ann Fam Med. 2020; 18(2): 148–155.
24. Rutman MP, Horn JR, Newman DK, Stefanacci RG. Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug-Drug Interactions. Clin Drug Investig. 2021; 41(4): 293–302.
25. www.go.drugbank.com., přístup 1. 6. 2024.
26. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009; 8(6): 615–626.
27. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001; 41(6): 636–44.
28. Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol. 2021; 18(11): 686–700.
29. Naseri A, Sadigh-Eteghad S, Seyedi-Sahebari S, et al. Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis. Dement Neuropsychol. 2023 May 29; 17: e20220053.
30. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018 Apr 25; 361: k1315.
31. Yoshida A, Fujino T, Maruyama S, et al. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder. J Pharmacol Sci. 2010; 112(2): 142–50.
32. Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022; 41(8): 1928–1933.